IFNG and myelodysplastic syndrome: We conducted a phase I trial of IFN-γ in combination with DLI in participants with relapsed AML/MDS after alloSCT (NCT04628338; Figure 1; clinical protocol in Supplemental Data 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.190655DS1).